Associated Papers
Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.
Krebs K et al.
Npj Genomic Medicine, 2026
41549095 (PubMed )
Supplement: 41525_2025_549_MOESM2_ESM.xlsx › Supplementary_Data_8
The variation landscape of CYP2D6 in a multi-ethnic Asian population.
Maulana Y et al.
Scientific Reports, 2024
Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations.
Twesigomwe D et al.
Clinical Pharmacology and Therapeutics, 2023
36111505 (PubMed )
Supplement: CPT-113-643-s001.pdf
Targeted haplotyping in pharmacogenomics using Oxford Nanopore Technologies' adaptive sampling.
Deserranno K et al.
Frontiers in Pharmacology, 2023
38026945 (PubMed )
Supplement: DataSheet1.ZIP › SupplementaryMaterials › SupplementaryMaterials_Tables_S4-S9.xlsx › HG00190_R10.4.1_AldyCalls
Characterization of Novel CYP2D6 Alleles across Sub-Saharan African Populations.
Wang WY et al.
Journal of Personalized Medicine, 2022
36294714 (PubMed )
Supplement: jpm-12-01575-s001.zip › Supplemental_Table_S4__Allele_Variant_List.xlsx › Table
The Identification of Novel CYP2D6 Variants in US Hmong: Results From Genome Sequencing and Clinical Genotyping.
Wen YF et al.
Frontiers in Pharmacology, 2022
Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.
He ZX et al.
Drug Metabolism Reviews, 2015
Catalytic roles of CYP2D6.10 and CYP2D6.36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae.
Hanioka N et al.
Biochemical Pharmacology, 2006
Select a paper to view details